Showing results (41-50 of 59) with videos related to
Sort By:
Pageof 6
JCI Insight|December 8, 2021
Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancerNavonil De Sarkar, Sayan Dasgupta, Payel Chatterjee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2023
Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder CancerSophia C Kamran, Yuzhen Zhou, Keisuke Otani, et al.Journal for Immunotherapy of Cancer|June 20, 2020
Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancerAnanth Annapragada, Andrew Sikora, Catherine Bollard, et al.The Journal of Clinical Investigation|August 9, 2013
Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironmentBrent A Hanks, Alisha Holtzhausen, Katherine S Evans, et al.Nature Cancer|July 14, 2021
Accelerating precision medicine in metastatic prostate cancerJoaquin Mateo, Rana McKay, Wassim Abida, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2016
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaDavid J Kwiatkowski, Toni K Choueiri, André P Fay, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 15, 2025
Optimizing participant and community engagement in cancer genomic sequencing researchNorah L Crossnohere, Anne L R Schuster, Cindy K Blair, et al.JCO Precision Oncology|July 8, 2026
Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision OncologySophia C Kamran, Monica Borges, Jeff Michalski, et al.Nature Cancer|January 9, 2025
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinomaTejas Jammihal, Renee Maria Saliby, Chris Labaki, et al.Cancer Immunology Research|May 12, 2018
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell CarcinomaRana R McKay, Dominick Bossé, Wanling Xie, et al.Pageof 6